1[1]Baquero F.Resistance to quinolones in gram-negative microorganisms:mechanisms and prevention.Eur Urol,1990,17(Suppl 1):3-12. 被引量：1
2[2]Dong Y,Zhao X,Domagala J,et al.Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus.Antimicrob Agents Chemother,1999,43:1756-1758. 被引量：1
3[3]Zhao X,Drlica K.Restricting the selection of antibiotic-resistant mutants:a general strategy derived from fluoroquinolones studies.Clin Infect Dis,2001,33(Suppl):S147-S156. 被引量：1
5[5]Firsov AA,Vostrov SN,Lubenko IY,et al.In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.Antimicrob Agents Chemother,2003,47:1604-1613. 被引量：1
6[6]Cui J,Liu Y,Wang R,et al.The mutant selection window in rabbits infected with Staphylococcus aureus.J Infect Dis,2006,194:1601-1608. 被引量：1
7[7]Liu Y,Cui J,Wang R,et al.Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy:concurrent bacterial eradication and acquisition of resistance.J Antimicrob Chemother,2005,56:1172-1175. 被引量：1
8[8]Craig WA.Pharmocokinetic/pharmocosynamic parameters:rational for antibacterial dosing of mice and men.Clin Infect Dis,1998,26:1-12. 被引量：1
9[9]Gould IM,MacKenzie FM.Antibiotic exposure as a risk factor for emergence of resistance:the influence of concentration.Symp Ser Soc Appl Microbiol,2002,92:78s-84s. 被引量：1
2Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolones studies[J]. Clin Infect Dis, 2001, 33(Suppl): S147-S156. 被引量：1
3Drlica K. The mutant selection concentration and antimicrobial resistance[J]. J Antimicrob Chemother, 2003, 52(1):11-17. 被引量：1
4Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window[J]. J Infect Dis, 2002, 185(4): 561-565. 被引量：1
5Zhao X, Eisner W, Perl-Rosenthal N, et al. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible and ciprofloxacin-resistant Staphylococcus aureus[J]. Antimicrob Agents Chemother, 2003, 47(3): 1023-1027. 被引量：1
6Dong Y, Zhao X, Domagala J, et al. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium boris BCG and Staphylococcus aureus[J]. Antimierob Agents Chemother, 1999, 43(7): 1756-1758. 被引量：1
5Demain AL, Sanchez S, Microbial drug discovery: 80 years of progress[J]. J Antibiot (Tokyo), 2009,62(1):5-16. 被引量：1
6Roberts JA, Kruger P, Paterson DL, et al. Antibiotic resistance-what's dosing got to do with it[J]? Crit Care Med, 2008,36(8):2433-2440. 被引量：1
7Dong Y, Zhao X, Domagala J, et al. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium boris BCG and Staphylococcus aureus [J]. Antimicrob Agents Chemother, 1999,43(7):1756-1758. 被引量：1
9Smith HJ, Nichol KA, Hoban D J, et al. Stretching the mutant prevention concentration (MPC) beyond its limits [J]. J Antimicrob Chemother, 2003,51(6):1323-1325. 被引量：1
10Zhao X. Clarification of MPC and the mutant selection window concept[J]. J Antimicrob Chemother, 2003,52(4):731. 被引量：1
